Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis
Drug-induced liver injury (DILI) is a disease that remains difficult to predict and prevent from a clinical perspective, as its occurrence is hard to fully explain by the traditional mechanisms. In recent years, the risk of the DILI for microbiota dysbiosis has been recognized as a multifactorial pr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.972518/full |
| _version_ | 1811273936022798336 |
|---|---|
| author | Lihong Fu Lihong Fu Yihan Qian Zhi Shang Xuehua Sun Xiaoni Kong Yueqiu Gao Yueqiu Gao |
| author_facet | Lihong Fu Lihong Fu Yihan Qian Zhi Shang Xuehua Sun Xiaoni Kong Yueqiu Gao Yueqiu Gao |
| author_sort | Lihong Fu |
| collection | DOAJ |
| description | Drug-induced liver injury (DILI) is a disease that remains difficult to predict and prevent from a clinical perspective, as its occurrence is hard to fully explain by the traditional mechanisms. In recent years, the risk of the DILI for microbiota dysbiosis has been recognized as a multifactorial process. Amoxicillin-clavulanate is the most commonly implicated drug in DILI worldwide with high causality gradings based on the use of RUCAM in different populations. Antibiotics directly affect the structure and diversity of gut microbiota (GM) and changes in metabolites. The depletion of probiotics after antibiotics interference can reduce the efficacy of hepatoprotective agents, also manifesting as liver injury. Follow-up with liver function examination is essential during the administration of drugs that affect intestinal microorganisms and their metabolic activities, such as antibiotics, especially in patients on a high-fat diet. In the meantime, altering the GM to reconstruct the hepatotoxicity of drugs by exhausting harmful bacteria and supplementing with probiotics/prebiotics are potential therapeutic approaches. This review will provide an overview of the current evidence between gut microbiota and DILI events, and discuss the potential mechanisms of gut microbiota-mediated drug interactions. Finally, this review also provides insights into the “double-edged sword” effect of antibiotics treatment against DILI and the potential prevention and therapeutic strategies. |
| first_indexed | 2024-04-12T23:09:49Z |
| format | Article |
| id | doaj.art-d1c15bcf60bb4170ae5af58c8add4ec5 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T23:09:49Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-d1c15bcf60bb4170ae5af58c8add4ec52022-12-22T03:12:50ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-09-01910.3389/fmed.2022.972518972518Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosisLihong Fu0Lihong Fu1Yihan Qian2Zhi Shang3Xuehua Sun4Xiaoni Kong5Yueqiu Gao6Yueqiu Gao7Central Laboratory, Department of Liver Diseases, ShuGuang Hospital, Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaInstitute of Infection Diseases, Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaCentral Laboratory, Department of Liver Diseases, ShuGuang Hospital, Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaCentral Laboratory, Department of Liver Diseases, ShuGuang Hospital, Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaCentral Laboratory, Department of Liver Diseases, ShuGuang Hospital, Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaCentral Laboratory, Department of Liver Diseases, ShuGuang Hospital, Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaCentral Laboratory, Department of Liver Diseases, ShuGuang Hospital, Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaInstitute of Infection Diseases, Shanghai University of Chinese Traditional Medicine, Shanghai, ChinaDrug-induced liver injury (DILI) is a disease that remains difficult to predict and prevent from a clinical perspective, as its occurrence is hard to fully explain by the traditional mechanisms. In recent years, the risk of the DILI for microbiota dysbiosis has been recognized as a multifactorial process. Amoxicillin-clavulanate is the most commonly implicated drug in DILI worldwide with high causality gradings based on the use of RUCAM in different populations. Antibiotics directly affect the structure and diversity of gut microbiota (GM) and changes in metabolites. The depletion of probiotics after antibiotics interference can reduce the efficacy of hepatoprotective agents, also manifesting as liver injury. Follow-up with liver function examination is essential during the administration of drugs that affect intestinal microorganisms and their metabolic activities, such as antibiotics, especially in patients on a high-fat diet. In the meantime, altering the GM to reconstruct the hepatotoxicity of drugs by exhausting harmful bacteria and supplementing with probiotics/prebiotics are potential therapeutic approaches. This review will provide an overview of the current evidence between gut microbiota and DILI events, and discuss the potential mechanisms of gut microbiota-mediated drug interactions. Finally, this review also provides insights into the “double-edged sword” effect of antibiotics treatment against DILI and the potential prevention and therapeutic strategies.https://www.frontiersin.org/articles/10.3389/fmed.2022.972518/fullgut microbiotadrug-induced liver injuryantibioticsgut liver axisprobiotics |
| spellingShingle | Lihong Fu Lihong Fu Yihan Qian Zhi Shang Xuehua Sun Xiaoni Kong Yueqiu Gao Yueqiu Gao Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis Frontiers in Medicine gut microbiota drug-induced liver injury antibiotics gut liver axis probiotics |
| title | Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis |
| title_full | Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis |
| title_fullStr | Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis |
| title_full_unstemmed | Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis |
| title_short | Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis |
| title_sort | antibiotics enhancing drug induced liver injury assessed for causality using roussel uclaf causality assessment method emerging role of gut microbiota dysbiosis |
| topic | gut microbiota drug-induced liver injury antibiotics gut liver axis probiotics |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.972518/full |
| work_keys_str_mv | AT lihongfu antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis AT lihongfu antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis AT yihanqian antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis AT zhishang antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis AT xuehuasun antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis AT xiaonikong antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis AT yueqiugao antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis AT yueqiugao antibioticsenhancingdruginducedliverinjuryassessedforcausalityusingrousseluclafcausalityassessmentmethodemergingroleofgutmicrobiotadysbiosis |